Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Rapid Dose Therapeutics Corp C.DOSE

Alternate Symbol(s):  RDTCF

Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. It provides disruptive drug delivery technologies designed to improve patient outcomes. Its flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream... see more

CSE:DOSE - Post Discussion

Rapid Dose Therapeutics Corp > The reasons I won't sell my DOSE shares (& plan to buy more)
View:
Post by Profiteer on Dec 04, 2022 11:56am

The reasons I won't sell my DOSE shares (& plan to buy more)

Regardless of the retail expansion...
Despite the filing delays... 

The research collaboration with McMaster University (a credible institution) has the potential to introduce a disruptive product:
  1. A vaccine strip that can solve the vaccine delivery & logistics issue, without the need of expensive cold storage distribution & no-needle injections.
  2. We're not just talking about Covid, but a viable drug delivery alternative for the pharmaceutical industry in general.
  3. It's a scalable product with indications for use worldwide.
  4. The research has already presented positive results. Further progress in research will likely result in media exposure/announcement (potentially resulting in an uptrend spike)
  5. One of 5 Canadian companies accepted into the Venture Mentoring Services (US/CAN) collaboration. If there wasn't aat least a viable business model, they would not have been selected.
Comment by cashworx83 on Dec 05, 2022 12:35am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities